Significance of cardiovascular comorbidity in patients with chronic myelomonocytic leukemiaBedeutung der kardiovaskulären Komorbidität bei Patienten mit chronischer myelomonozytärer Leukämie

被引：0
作者：
David Lackner
Klaus Geissler
机构：
[1] Sigmund Freud University,Medical School
[2] Hospital Hietzing,Department of Internal Medicine V with Hematology, Oncology and Palliative Care
来源：
Wiener Medizinische Wochenschrift | 2023年 / 173卷
关键词：
Chronic myelomonocytic leukemia; Cardiovascular disease; Survival; Time to transformation; Coronary heart disease; Chronische myelomonozytäre Leukämie; Kardiovaskuläre Erkrankungen; Überleben; Dauer bis zur Transformation; Koronare Herzkrankheit;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
In a retrospective study, we analyzed the prevalence of common cardiovascular comorbidities in 310 patients with chronic myelomonocytic leukemia (CMML), their potential prognostic impact, and potential correlations with laboratory and molecular features. 115 (36%) patients had a documented cardiovascular comorbidity. In these patients, coronary heart disease 41/115 (36%), atrial fibrillation 34/115 (29%), and hypertension 75/115 (64%) were documented. None of these conditions had a significant impact on survival. Unexpectedly, patients with cardiovascular comorbidity had a lower number of circulating blasts and a lower prevalence of EZH2 mutations. Moreover, time to transformation was significantly longer in these patients. Cardiovascular comorbidity does not seem to have a major impact on prognosis in CMML patients. The unexpected lower transformation rate in these patients needs to be further investigated.
引用
收藏
页码：27 / 33
页数：6
相关论文
共 90 条
  • [1] Bennett JM(1982)Proposals for the classification of the myelodysplastic syndromes Br J Haematol 51 189-199
  • [2] Catovsky D(2002)The World Health Organization (WHO) classification of the myeloid neoplasms Blood 100 2292-2302
  • [3] Daniel MT(2009)The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes Blood 114 937-951
  • [4] Vardiman JW(2016)The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia Blood 127 2391-2405
  • [5] Harris NL(2002)Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients Blood 99 840-849
  • [6] Brunning RD(2013)Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes Leukemia 27 1504-1510
  • [7] Vardiman JW(2013)Prognostic score including gene mutations in chronic myelomonocytic leukemia J Clin Oncol 31 2428-2436
  • [8] Thiele J(2016)Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia Blood 128 1408-1417
  • [9] Arber DA(2021)Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia Eur J Haematol 107 265-274
  • [10] Arber DA(1988)Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases J Clin Oncol 6 1417-1424
123456789